Search

Displaying results 5141 - 5150 of 5365 in total
  1. Drug

    Influenza A Virus A/Victoria/4897/2022 IVR-238 (H1N1) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB17994
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes

  2. Drug

    Influenza A virus A/Victoria/4897/2022 IVR-238 (H1N1) Antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB17997
    ApprovedWithdrawn

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes

  3. Drug

    Influenza A virus A/Darwin/9/2021 IVR-228 (H3N2) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB16924
    ApprovedWithdrawn

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes

  4. Drug

    Influenza A Virus A/Sydney/5/2021 SAN-013 (H1N1) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB17751
    ApprovedWithdrawn

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes

  5. Drug

    Influenza A virus A/Thailand/8/2022 IVR-237 (H3N2) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB19320
    ApprovedWithdrawn

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes

  6. Drug

    Influenza A virus A/Croatia/10136RV/2023 X-425A (H3N2) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB22670
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes

  7. Drug

    Influenza A virus A/Croatia/10136RV/2023 X-425A (H3N2) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB22672
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes

  8. Drug

    Vicadrostat

    go.drugbank.com/drugs/DB21693
    Investigational

    Vicadrostat has a monoisotopic molecular weight of 317.06 Da.

  9. Drug

    Nizubaglustat

    go.drugbank.com/drugs/DB21603
    Investigational

    Nizubaglustat has a monoisotopic molecular weight of 433.23 Da.

  10. Drug

    Mersalyl

    go.drugbank.com/drugs/DB09338
    Experimental

    The sodium salt of a mercury-containing derivative of salicylamide, was formerly used (often in combination with theophylline) to treat edema, due to its powerful diuretic properties [L1577].